Stéphane Le Vu et al.: "Increased risks of myocarditis and pericarditis during the first week following vaccination, and particularly after the second dose...largest risk in those aged 18 to 24 years

Largest associations are observed for myocarditis following mRNA-1273 vaccination in persons aged 18 to 24 years; a substantial burden of both myocarditis & pericarditis across other age groups also

Bottom line and this study out today is telling us what we already knew from prior studies across the last over one year. The study shows that vaccination/injection/inoculation using both mRNA vaccines (Pfizer and Moderna) was related to an increased risk of myocarditis and pericarditis within the first 7 days post vaccination. The study showed that the relationships/associations were especially marked after the second dose, and were existent for both males and females. The study also revealed a trend of enhanced risks towards younger age groups. Moreover, a significant risk was also emerged among males greater than 30 years of age to develop myocarditis and among females over 30 years of age to develop a pericarditis post vaccination.

Specifically, this study (Figures 1 and 2) showed us that for the two vaccines, ‘the risk of myocarditis was increased in the seven days post vaccination. For the BNT162b2 vaccine (Pfizer), odds ratios were 1.8 (95% confidence interval [CI]: 1.3–2.5) for the first dose and 8.1 (95% CI, 6.7–9.9) for the second. The association was stronger for the mRNA-1273 vaccine (Moderna) with odds-ratios of 3.0 (95% CI, 1.4–6.2) for the first dose and 30 (95% CI, 21–43) for the second. The risk of pericarditis was increased in the seven days following the second dose of both vaccines, with odds ratios of 2.9 (95% CI, 2.3–3.8) for the BNT162b2 vaccine and 5.5 (95% CI, 3.3–9.0) for the mRNA-1273 vaccine. Vaccination in the previous 8 to 21 days, with either the BNT162b2 or mRNA-1273 vaccine was not associated with a risk of myocarditis or pericarditis.’

SOURCE:

Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines

Figure 1 ENLARGED

Figure 2 ENLARGED

‘Subgroup estimates by sex and age classes

The risk of myocarditis was substantially increased within the first week post vaccination in both males and females (Fig. 1 and Table S2). Odds-ratios associated with the second dose of the mRNA-1273 vaccine were consistently the highest, with values up to 44 (95% CI, 22–88) and 41 (95% CI, 12–140), respectively in males and females aged 18 to 24 years but remaining high in older age groups. Odds-ratios for the second dose of the BNT162b2 vaccine tended to decrease with age, from 18 (95% CI, 9–35) and 7.1 (95% CI, 1.5–33), respectively in males and females aged 12 to 17 years, down to 3.0 (95% CI, 1.5–5.9) and 1.9 (95% CI, 0.39–9.3), respectively in males and females aged 40 to 51 years.

An increased risk of pericarditis was also found in the first week after the second dose of either of the mRNA vaccines among both males and females (Fig. 2 and Table S3). Odds-ratios for the second dose of the BNT162b2 vaccine showed a downward trend across age groups with values up to 6.8 (95% CI, 2.3–20) and 10 (95% CI, 2.5–41), respectively in males and females aged 12 to 17 years. The second dose of the mRNA-1273 vaccine was associated with pericarditis among males and among females only within age 30 to 39 years (odds-ratio 20 [95% CI, 3.5–110]) and age 40 to 50 years (odds-ratio 13 [95% CI, 3.5–49]).’